Bridging science and clinical operability for neurologic monoclonal antibodies

As the diversity of monoclonal antibody (mAb) treatments for neurologic diseases grows, the real-world success of these breakthroughs is increasingly less defined by their mechanisms of action and more by the clinical operational protocols surrounding them. 

These operational protocols have matured beyond standard clinical practices to include rigorous safety governance, Risk Evaluation and Mitigation Strategies (REMS), disciplined imaging cadence, and treatment delivery options that are more flexible and patient-centric. For any new neurologic mAb to succeed, its development must bridge the gap between scientific discovery and daily clinical execution. This necessitates a rigorous development playbook with priorities specific to this class of therapies.

This whitepaper explores the history of innovations in neurologic mAbs and how they have shaped today’s clinical and regulatory picture, including operational essentials for today’s mAb developers.

Read to explore:

• The evolution of operational parameters for neurologic mAbs
• Indication-specific safety planning
• Alignment of delivery and monitoring protocols precisely with the therapy's risk profile 
• Clinical operational alignment that seamlessly integrates eligibility discipline, site capacity planning, and anticipation of complex regulatory mandates
• Rationalisation for patient-first approaches to accessibility and therapeutic delivery 
• Next-generation solutions in neurologic therapeutics, such as brain shuttle technologies
• A checklist of critical development considerations encompassing eligibility, monitoring, capacity, and policy compliance